Results 81 to 90 of about 26,042 (243)

Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis [PDF]

, 2017
Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use. Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF ...
Distler, J. H. W., Distler, O.
core  

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
A Quintas-Cardama, A Quintas-Cardama, A Quintas-Cardama, AJ Tipping, AJ Tipping, B Zhang, C Akgul, C Bellodi, G Gurel, H de Lavallade, H Konig, HG Jorgensen, HM Kantarjian, J Kuroda, KJ Aichberger, L Legros, M Copland, M Copland, NB Heaney, R Chen, R Tang, RG Powell, RM Stone, S Chu, SM Graham, SV Sharma, T Kobayashi, Y Chen   +27 more
core   +1 more source

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19 [PDF]

, 2022
Leila N. Atmowihardjo, Job R. Schippers, Imke H. Bartelink, Pierre M. Bet, Nienke van Rein, Keith Purdy, David Cavalla, Valérie Comberiati, Andrew B. McElroy, Sue D. Snape, Harm Jan Bogaard, Leo Heunks, Nicole P. Juffermans, Marcus J. Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman   +16 more
openalex   +1 more source

Quality of Life and Adherence to Tyrosine Kinase Inhibitors Among Pediatric, Adolescent, and Young Adult Chronic Myeloid Leukemia Patients: A Systematic Review

Pediatric Blood &Cancer, Volume 72, Issue 6, June 2025.
ABSTRACT The chronic nature of chronic myeloid leukemia (CML) has a negative impact on patients’ health‐related quality of life (HRQOL) and the need for prolonged oral tyrosine kinase inhibitors (TKIs) poses a risk to low or nonadherence over time. This systematic review seeks to analyze HRQOL outcomes and adherence to TKIs among pediatric, adolescent,
Rachel S. Werk, Casey J. Mehrhoff, Sherif M. Badawy   +2 more
wiley   +1 more source

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Advances in Hematology, 2010
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec)
K. G. Koffi, D. C. Nanho, E. N'dathz, P. Kouehion, R. Dissieka, A. Attia, K. Mozard, A. Tolo, K. Boidy, N. Meité, R. Ayemou, M. Sekongo, N. Tea, I. Sanogo   +13 more
doaj   +1 more source

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?

Turkish Journal of Hematology, 2016
INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM
Olga Meltem Akay, Fezan Şahin Mutlu, Zafer Gülbaş   +2 more
doaj   +1 more source

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide [PDF]

, 2010
A randomized, multicenter, open-label, phase 3 study of patients with progressive, recurrent glioblastoma multiforme (GBM) for whom front-line therapy had failed was conducted.
Dresemann, G, Engel, E, Fluge, O, Heinrich, B, Hosius, C, Karup-Hansen, A, Krex, D, Mayer-Steinacker, R, Mehdorn, M, Nikolova, Z, Nowak, A, Olver, I N, Parker, R, Rosenthal, M A, Schleyer, E, Sieder, C, Sorenson, G, Steinbach, J P, Wagner, W, Wedding, U, Weller, M   +20 more
core   +1 more source

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. [PDF]

, 2008
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic myeloid leukaemia (CP-CML) patients responsive to interferon-alpha (IFNα), in stable complete cytogenetic response (CCR) but with persistent PCR positivity.
B. De Angelis, B. Rotoli, D. Divero, F. Mandelli, F. P.a.n.e., F. Quarantelli, G. Alimena, I. Carmosino, IZZO, BARBARA, L. Luciano, M. Breccia, M. Mancini, N. Nanni, PICARDI, MARCO, R. La tagliata   +14 more
core   +1 more source

18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report

Case Reports in Oncological Medicine, 2011
Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
Kazunori Otsuka, Masahiro Takahashi, Hiroshi Nanjo, Hideaki Miyazawa, Masatake Iida, Yuki Abe, Mario Jin, Hirohide Onishi, Manabu Hashimoto, Yuzo Yamamoto, Hiroyuki Shibata   +10 more
doaj   +1 more source

Chronic Myeloid Leukemia in pediatrics patients: current approach [PDF]

, 2008
Chronic myeloid leukemia (CML) is a rare event in childhood, comprising of less than 5% of all leukemia cases in this age group. CML is characterized by the presence of a specific molecular marker, the Ph+ chromosome, which is responsible for almost all ...
Lee, Maria Lúcia de Martino
core   +1 more source